A Phase 2 interventional study of pertuzumab and paclitaxel in Ovarian Cancer, sponsored by Hoffmann-La Roche. Completed at 34 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-04.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Ovarian Neoplasms by Hoffmann-La Roche — none open to participants now, 3 under way, none of them phase 3. Ovarian Neoplasms · Hoffmann-La Roche.
Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2005, is one of 12 in phase 2, and was the 23rd registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche is open now. The open studies under Ovarian Neoplasms, anywhere →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 100 across the 30 interventional studies, 63 across the 5 observational. Of the 31 that completed or were terminated, 14 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
1 of the studies in Ovarian Neoplasms by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pertuzumab · Drug: paclitaxel · Drug: gemcitabine · Drug: carboplatin
Drug: paclitaxel · Drug: gemcitabine · Drug: carboplatin
Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
175 mg/m2 IV every 3 weeks for 6 cycles
1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
Percentage of Participants With Disease Progression or Death
Disease progression was assessed according to RECIST (Response Evaluation Criteria In Solid Tumors), for participants with measurable disease, or by changes in CA 125 (Cancer Antigen 125) according to GCIG (Gynecologic Cancer Inter Group) for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Progression-Free Survival
Progression-free survival was defined as the time from first administration of study drug (Study Day 1) to documented disease progression or death, whichever occurred earlier. Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Kaplan-Meier Probability of No Disease or Progression at 1 Year
The probability of being event free (no disease progression or death events) at 1 year in participants remaining at risk.
Time frame: 1 year
Percentage of Participants With a Best Overall Confirmed Response Based on Combined CA 125 and RECIST Measurements
Response by tumor measurement occurred if there was documented and confirmed complete response (CR) or partial response (PR). For all participants, response was assessed by both the RECIST and by CA 125 levels, according to whether the participant had measurable or non-measurable disease at baseline. Response according to CA 125 levels was defined as at least a 50% reduction from baseline. The decrease had to be confirmed and maintained for at least 28 days. The confirmatory sample must have been less than or equal to the previous sample (within an assay variability of 10%). For overall response, the response categories were "response", "stable disease" and "progressive disease". Stable disease included 1) stable disease as defined by RECIST for solid tumors and 2) CA 125 levels that had not met the definition of "response" or "progressive disease".
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Duration of Response
For participants who achieved a response, the duration of response was defined as the interval between initial documentation of response to the first documentation of disease progression or death. Participants who responded and did not progress or die while on study or while being followed were censored at the last valid tumor or CA 125 measurement.
Time frame: Day 15 of Cycles 2, 4, 6, and Day 15 of all Cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Kaplan-Meier Probability of Maintaining a Response to at Least 1 Year
Time frame: 1 year
Percentage of Participants With Disease Progression
Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression
Time to Progressive Disease
The time to progressive disease is the interval of time from date of first dose of study medication to date of first documentation of progressive disease by either RECIST or CA 125 criteria. Participants who never progressed while being followed were censored at the last valid tumor measurement or CA 125 measurement.
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression
Kaplan-Meier Probability of Being Progression Free at 1 Year
Time frame: 1 year
Time To Response
Time to response was the date of first dose of study medication to the date of the first documentation of response, according to CA 125 criteria for all participants or response according to RECIST criteria for participants with measurable disease. If response was evaluable by both criteria, then the date of response was for the earlier of the two events.
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment
Percentage of Participants Who Died
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment
Overall Survival
Survival was the interval of time from date of first dose of study medication to date of death at any time. Participants who had not died were censored at the date of last contact when they were known to be alive.
Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment
Kaplan-Meier Probability of Being Alive at 1 Year
Time frame: 1 year
| Milestone | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Started | 75 | 74 |
| Completed | 1 | 1 |
| Not completed | 74 | 73 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lack of efficacy | 66 | 62 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 7 |
| Withdrew: Other | 3 | 1 |
Disease progression was assessed according to RECIST (Response Evaluation Criteria In Solid Tumors), for participants with measurable disease, or by changes in CA 125 (Cancer Antigen 125) according to GCIG (Gynecologic Cancer Inter Group) for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.
| percentage of participants | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Percentage of Participants With Disease Progression or Death | 87.8 | 80.0 |
Progression-free survival was defined as the time from first administration of study drug (Study Day 1) to documented disease progression or death, whichever occurred earlier. Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.
| weeks | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Progression-Free Survival | 34.1 (31 to 38) | 40.0 (33 to 43) |
Response by tumor measurement occurred if there was documented and confirmed complete response (CR) or partial response (PR). For all participants, response was assessed by both the RECIST and by CA 125 levels, according to whether the participant had measurable or non-measurable disease at baseline. Response according to CA 125 levels was defined as at least a 50% reduction from baseline. The decrease had to be confirmed and maintained for at least 28 days. The confirmatory sample must have been less than or equal to the previous sample (within an assay variability of 10%). For overall response, the response categories were "response", "stable disease" and "progressive disease". Stable disease included 1) stable disease as defined by RECIST for solid tumors and 2) CA 125 levels that had not met the definition of "response" or "progressive disease".
| percentage of participants | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Percentage of Participants With a Best Overall Confirmed Response Based on Combined CA 125 and RECIST Measurements | 74.3 | 68.0 |
For participants who achieved a response, the duration of response was defined as the interval between initial documentation of response to the first documentation of disease progression or death. Participants who responded and did not progress or die while on study or while being followed were censored at the last valid tumor or CA 125 measurement.
| weeks | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Duration of Response | 28.7 (22 to 48) | 37.0 (25 to 43) |
| percent | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Kaplan-Meier Probability of Maintaining a Response to at Least 1 Year | 18 | 18 |
Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.
| percentage of participants | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Percentage of Participants With Disease Progression | 83.8 | 76.0 |
The time to progressive disease is the interval of time from date of first dose of study medication to date of first documentation of progressive disease by either RECIST or CA 125 criteria. Participants who never progressed while being followed were censored at the last valid tumor measurement or CA 125 measurement.
| weeks | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Time to Progressive Disease | 34.3 (27 to 48) | 37.3 (29 to 47) |
| percent | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Kaplan-Meier Probability of Being Progression Free at 1 Year | 24 | 19 |
The probability of being event free (no disease progression or death events) at 1 year in participants remaining at risk.
| percent | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Kaplan-Meier Probability of No Disease or Progression at 1 Year | 24 | 21 |
Time to response was the date of first dose of study medication to the date of the first documentation of response, according to CA 125 criteria for all participants or response according to RECIST criteria for participants with measurable disease. If response was evaluable by both criteria, then the date of response was for the earlier of the two events.
| weeks | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Time To Response | 6.0 (5 to 17) | 6.3 (5 to 15) |
| percentage of participants | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Percentage of Participants Who Died | 45.9 | 41.3 |
Survival was the interval of time from date of first dose of study medication to date of death at any time. Participants who had not died were censored at the date of last contact when they were known to be alive.
| months | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Overall Survival | 28.2 (1 to 52) | NA (1 to 34) |
| percent | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Kaplan-Meier Probability of Being Alive at 1 Year | 88 | 85 |
Collected over Adverse events were collected from the date of randomization until 28 days after the last dose of the pertuzumab and/ or standard chemotherapy and continuously until end of study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemotherapy + Pertuzumab | — | 20/75 (26.7%) | 72/75 (96%) |
| Chemotherapy | — | 12/74 (16.2%) | 68/74 (91.9%) |
| Event | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| Drug hypersensitivityImmune system disorders | 4/75 | 0/74 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/75 | 3/74 |
| Abdominal painGastrointestinal disorders | 2/75 | 1/74 |
| DiarrhoeaGastrointestinal disorders | 2/75 | 0/74 |
| Intestinal obstructionGastrointestinal disorders | 2/75 | 0/74 |
| VomitingGastrointestinal disorders | 2/75 | 0/74 |
| PyrexiaGeneral disorders | 2/75 | 0/74 |
| AscitesGastrointestinal disorders | 1/75 | 1/74 |
| ConstipationGastrointestinal disorders | 0/75 | 1/74 |
| Large intesting perforationGastrointestinal disorders | 0/75 | 1/74 |
| Event | Chemotherapy + Pertuzumab | Chemotherapy |
|---|---|---|
| NauseaGastrointestinal disorders | 44/75 | 33/74 |
| DiarrhoeaGastrointestinal disorders | 44/75 | 14/74 |
| NeutropeniaBlood and lymphatic system disorders | 36/75 | 43/74 |
| FatigueGeneral disorders | 30/75 | 27/74 |
| AlopeciaSkin and subcutaneous tissue disorders | 22/75 | 25/74 |
| VomitingGastrointestinal disorders | 24/75 | 22/74 |
| ConstipationGastrointestinal disorders | 20/75 | 22/74 |
| AnaemiaBlood and lymphatic system disorders | 19/75 | 21/74 |
| Decreased appetiteMetabolism and nutrition disorders | 19/75 | 4/74 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/75 | 18/74 |
All participants who received randomized treatment (All Treated Population, for Efficacy Analyses); 1 participant was randomized to the chemotherapy arm but received pertuzumab+chemotherapy and is thus included in this arm for all analyses.
| Age, Continuous(years) | Chemotherapy + Pertuzumab | Chemotherapy | Total |
|---|---|---|---|
| Mean | 58.1 ± 10.16 | 55.3 ± 11.41 | 56.7 ± 10.86 |
| Sex: Female, Male(Participants) | Chemotherapy + Pertuzumab | Chemotherapy | Total |
|---|---|---|---|
| Female | 74 | 75 | 149 |
| Male | 0 | 0 | 0 |
The record gives a start of Dec 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab